Bagnasco, D.; Bondi, B.; Caminati, M.; Nicola, S.; Pini, L.; Milanese, M.; Brussino, L.; Senna, G.; Canonica, G.W.; Braido, F.
Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab. Biomedicines 2024, 12, 960.
https://doi.org/10.3390/biomedicines12050960
AMA Style
Bagnasco D, Bondi B, Caminati M, Nicola S, Pini L, Milanese M, Brussino L, Senna G, Canonica GW, Braido F.
Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab. Biomedicines. 2024; 12(5):960.
https://doi.org/10.3390/biomedicines12050960
Chicago/Turabian Style
Bagnasco, Diego, Benedetta Bondi, Marco Caminati, Stefania Nicola, Laura Pini, Manlio Milanese, Luisa Brussino, Gianenrico Senna, Giorgio Walter Canonica, and Fulvio Braido.
2024. "Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab" Biomedicines 12, no. 5: 960.
https://doi.org/10.3390/biomedicines12050960
APA Style
Bagnasco, D., Bondi, B., Caminati, M., Nicola, S., Pini, L., Milanese, M., Brussino, L., Senna, G., Canonica, G. W., & Braido, F.
(2024). Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab. Biomedicines, 12(5), 960.
https://doi.org/10.3390/biomedicines12050960